CA 19-9: Biochemical and Clinical Aspects

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• CA 19-9 (carbohydrate antigen 19-9) is a widely used serum tumor marker for pancreatic cancer.
• It is synthesized by normal pancreatic, biliary, gastric, colon, endometrial, and salivary epithelia.
• Elevated CA 19-9 levels are observed in neoplastic diseases, but also in benign gastrointestinal disorders.

Purpose of the Study:

• To evaluate the clinical utility of CA 19-9 as a pancreatic cancer biomarker.
• To discuss the limitations of CA 19-9, including false negatives and positives.
• To review the status of alternative pancreatic cancer biomarkers.

Main Methods:

• Review of existing literature on CA 19-9 and pancreatic cancer biomarkers.
• Analysis of CA 19-9 performance characteristics (sensitivity, specificity, predictive value).
• Comparison of CA 19-9 with other proposed biomarkers.

Main Results:

• CA 19-9 shows a dramatic increase in pancreatic cancer but suffers from false negatives (Lewis a-b- genotype) and false positives in benign conditions.
• Its positive predictive value is 72.3%, rendering it unsuitable for screening.
• Numerous other biomarkers have been proposed but lack large-scale validation and sufficient sensitivity/specificity.

Conclusions:

• Despite significant limitations, CA 19-9 remains the sole pancreatic cancer marker currently in clinical use.
• No alternative biomarker has demonstrated the required performance for clinical adoption.
• Further research is needed to identify and validate more effective pancreatic cancer biomarkers.